How do you treat primary refractory diffuse large B cell lymphoma in elderly patients with good performance status?   

In general, age (by itself) is not a limitation for most of the available therapies for DLBCL elderly patients. Comorbidities and performance status are what drive the decision of what to use as next therapy. I usually recommend all the approved therapies for RR DLBCL. My limit for autologous transp...